Recherche
Enseignement
Solutions
S'identifier
FR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Advanced Cancer Translational Research Institute
Junji Tsurutani has not added Biography.
If you are Junji Tsurutani and would like to personalize this page please email our Author Liaison for assistance.
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.
Investigational new drugs 12, 2017 | Pubmed ID: 28660549
and Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in .
Molecular cancer therapeutics 01, 2019 | Pubmed ID: 30322949
Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
Breast cancer (Tokyo, Japan) Mar, 2019 | Pubmed ID: 30324551
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Cancer science Jan, 2019 | Pubmed ID: 30390416
Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Cancer medicine Mar, 2019 | Pubmed ID: 30701699
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
The Lancet. Oncology Jun, 2019 | Pubmed ID: 31047803
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
The Lancet. Oncology Jun, 2019 | Pubmed ID: 31047804
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
International journal of cancer May, 2019 | Pubmed ID: 31087550
Showa University
Toshimitsu Yamaoka1,
Motoi Ohba1,
Yuki Matsunaga2,
Junji Tsurutani1,
Tohru Ohmori3
1Advanced Cancer Translational Research Institute, Showa University,
2Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine,
3Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine
Confidentialité
Conditions d'utilisation
Politiques
Contactez-nous
RECOMMANDER À LA BIBLIOTHÈQUE
NEWSLETTERS JoVE
JoVE Journal
Collections de méthodes
JoVE Encyclopedia of Experiments
Archives
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Centre de ressources universitaires
Auteurs
Bibliothécaires
Accès
À PROPOS DE JoVE
Copyright © 2024 MyJoVE Corporation. Tous droits réservés.